By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Galena Biopharma  

310 N. State Street, Suite 208

Lake Oswego   Oregon  97034  U.S.A.
Phone: 1-503-400-7636 Fax: 1-503-400-6611


SEARCH JOBS


Industry
Pharmaceutical






Company News
Galena Biopharma  (GALE) Presents HER2 Screening Data Including Preliminary Leica Bond Oracle™ Results From the Phase 3 NeuVax™ (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) 12/11/2014 7:45:28 AM
Galena Biopharma  (GALE) Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition 12/8/2014 8:27:46 AM
Galena Biopharma  (GALE) To Present HER2 Screening Data From The Phase 3 Neuvax™ (Nelipepimut-S) Clinical Trial At The 2014 San Antonio Breast Cancer Symposium (SABCS) 12/8/2014 7:26:26 AM
Galena Biopharma  (GALE) Receives Notice Of Allowance Of U.S. Patent Application For GALE-401 (Anagrelide Controlled Release) Composition Of Matter 12/2/2014 11:54:44 AM
Galena Biopharma  (GALE) To Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition 12/1/2014 9:40:33 AM
Galena Biopharma  (GALE) To Present At The Oppenheimer 25th Annual Healthcare Conference 11/25/2014 11:40:03 AM
Lincoln Park Doubles Down On Oncology With $55M Galena Biopharma  (GALE) Bet 11/21/2014 6:21:04 AM
Galena Biopharma  (GALE) Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 11/18/2014 11:55:00 AM
Galena Biopharma  (GALE) To Present At The Stifel 2014 Healthcare Conference 11/13/2014 10:38:11 AM
Galena Biopharma  (GALE) Doses First Patient In Phase 2 Clinical Trial With Neuvax(TM) (Nelipepimut-S) In Combination With Herceptin® (Trastuzumab) To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients 11/11/2014 7:18:24 AM
12345678910...
//-->